From the Department of Medicine (Dr Wahidi) and the Department of Pharmacy (Dr Barbour), Duke University Medical Center; and the Medical University of South Carolina (Dr Silvestri).
Correspondence to: Momen M. Wahidi, MD, MBA, FCCP, Department of Internal Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Box 3683, Durham, NC 27710; e-mail: firstname.lastname@example.org
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Wahidi was an investigator on the multicenter trial of Fospropofol. Dr Silvestri was an investigator on the multicenter trial of Fospropofol; he was a recipient of grant funding from Olympus America and MGI Pharma for a project assessing fospropofol for bronchoscopy and from Allegro Diagnostics Corp for assessing malignancy in patients with abnormal chest radiographs. Dr Barbour has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
© 2012 American College of Chest Physicians
We appreciate the comments of Dr José and colleagues about our recent consensus statement in CHEST1 and thank them for bringing attention to HIV disease, wherein great advances have been accomplished. Continuous attention to this patient population is indeed essential.
Our article attempted to address the major issues on the use of topical anesthesia, analgesia, and sedation during bronchoscopy. Therefore, it was beyond the scope of our effort to address all possible interactions of medications with various disease states.
Our segment on benzodiazepines specifically mentioned the need for higher doses of midazolam in “HIV-infected patients with history of drug dependence” and did not advocate it in all patients with HIV. We do agree that precautions should be taken when using benzodiazepines in patients with HIV receiving antiretroviral therapy, as these medications are known to inhibit the cytochrome P450 enzyme 3A4, potentially leading to excessive sedation.2,3
Our consensus statement can serve as a general platform to guide administration of sedation to patients undergoing bronchoscopy. Optimal and safe sedation requires physicians to tailor regimens to individual patients after careful assessment of comorbidities, medication profile, and procedural needs.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.